



ABN 82 010 975 612

Level 18, 101 Collins Street  
Victoria 3000 Australia  
Telephone: + 61 7 3273 9133  
Facsimile: + 61 7 3375 1168  
[www.tbgbio.com](http://www.tbgbio.com)

1 December 2016

## **ASX Announcement Company Secretary Appointment / Resignation**

The Board of TBG Diagnostics Limited (ASX: TDL) (the **Company** or **TBG**) announces the appointment of Justyn Stedwell as Company Secretary. Justyn is a professional Company Secretary consultant with ten years' experience as a Company Secretary of ASX listed companies. He has completed a Bachelor of Commerce (Economics & Management) from Monash University, a Graduate Diploma of Accounting from Deakin University and a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia.

Justyn has been appointed following the resignation of Blair Lucas as Company Secretary. Blair has resigned due to a change in the strategic direction of his business. The Board thanks Blair for his contribution to the Company and wishes him well in his future endeavours.

For more information:

Justyn Stedwell  
Company Secretary  
+61 3 9041 6663

### **About TBG Diagnostics**

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020.

Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases.